Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,359 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06424665RecruitingPhase 1
Study of FZ-AD005 for advanced solid tumors
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Changsha, HunanAges 18–75 - NCT06428331RecruitingPhase 1
Study of SKB518 for advanced solid tumors
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
Shanghai, ChinaAges 18 years+ - NCT06425926RecruitingPhase 1/Phase 2
Study of GIM-531 in advanced solid tumors
This study tests a new oral drug, GIM-531, alone and in combination with an anti-PD-1 therapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Birmingham, AlabamaAges 18 years+ - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT06417554RecruitingPhase 1/Phase 2
Study of SHR-A2102 for advanced solid tumors
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06402201RecruitingPhase 1
First human trial of CDR404 for MAGE-A4 positive solid tumors
This trial tests an experimental treatment called CDR404 for people with certain advanced solid tumors. It is designed for those whose tumors have a specific protein (MAGE-A4) and who have already tried other treatments. The goal is to see if the treatment is safe and effective.
Miami, FloridaAges 18 years+ - NCT06414460RecruitingPhase 1/Phase 2
ISM3412 for advanced solid tumors with MTAP deletion
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT06400485RecruitingEarly Phase 1
Testing AMT-676 for advanced solid tumors
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Huntersville, North CarolinaAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Aurora, ColoradoAges 18 years+ - NCT06386146RecruitingPhase 1/Phase 2
New pill for advanced cancers with TP53 Y220C mutation
This trial tests a new pill called JAB-30355 for people with advanced cancers that have a specific genetic change (TP53 Y220C). It's for those who have already tried other treatments and are looking for a new option.
Denver, ColoradoAges 18 years+ - NCT05340881Recruiting
Light exposure program for young survivors of childhood brain tumors
This trial studies whether a structured light-exposure routine can improve symptoms like fatigue and how survivors feel day to day. It is aimed at children and teens who have recovered from a non–high-risk type of brain tumor and have mild to moderate fatigue.
Houston, TexasAges 10–18 - NCT05904665Recruiting
Blood methylation test to guide follow-up after colon cancer surgery
This study checks a special blood test (circulating tumor DNA methylation) to help guide follow-up after surgery for non-metastatic colon cancer. It may help find whether additional treatment or closer monitoring is needed based on the test results.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT06383884RecruitingPhase 2
Study of patritumab deruxtecan for NRG1 fusion-positive tumors
This trial tests a new drug called patritumab deruxtecan for people with advanced solid tumors that have an NRG1 fusion. The drug targets a protein called HER3 on cancer cells and may help shrink tumors or slow their growth.
SeoulAges 18 years+ - NCT06365840RecruitingPhase 2
Study of IMC-001 for advanced tumors with high mutations
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
GoyangAges 19 years+ - NCT06368921RecruitingPhase 1
Study of M1 virus injection for advanced solid tumors
This trial tests a virus called M1 (VRT106) that may be able to infect and destroy cancer cells. It's given by injection directly into a tumor, and is for people whose advanced solid tumors haven't responded to other treatments.
Guangzhou, GuangdongAges 18–75 - NCT06378593RecruitingPhase 1/Phase 2
Study of drug 3HP-2827 for tumors with FGFR2 changes
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06210815RecruitingPhase 1
Testing a new drug HLX42 for advanced solid tumors
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Guangdong, GuangzhouAges 18–75
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,359 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.